As of November 9, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of ENDRA Life Sciences Inc. The largest reported stake is ASP Isotopes Inc.'s, at 15.1%. 7 filings are on record since October 28, 2025 (Schedule 13D, October 8, 2026).
Sell to companies like ENDRA Life Sciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: ASP Isotopes Inc. · Sole voting: 0 · Shared voting: 254,015 · Sole dispositive: 0 · Shared dispositive: 254,015 · SCHEDULE 13D, 2026-10-08
- · Reporting person: Anthony DiGiandomenico · Sole voting: 196,692 · Shared voting: 0 · Sole dispositive: 196,692 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-06-29
- · Holder: Anthony DiGiandomenico · Percent: 9.99% · SCHEDULE 13D
- · Holder: S.H.N. Financial Investments Ltd. · Percent: 3% · Shares: 35,588 · SCHEDULE 13G/A
- · Holder: L1 Capital Global Opportunities Master Fund, Ltd. · Percent: 3% · Shares: 35,589 · SCHEDULE 13G/A
ENDRA Life Sciences Inc. has 7 Schedule 13D or 13G filings on record since 2025-10-28. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-03-25 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ASP Isotopes Inc. | 15.1% | 254,015 | SCHEDULE 13D, 2026-10-08 | 2026-10-01 |
| 9.99% | 115,477 | SCHEDULE 13G, 2025-10-30 | 2025-10-23 | |
| ATW Master Fund V LP | 9.9% | 116,024 | SCHEDULE 13G, 2025-10-28 | 2025-10-16 |
| 9.9% | 196,692 | SCHEDULE 13D/A, 2026-06-29 | 2026-06-25 | |
| S.H.N. Financial Investments Ltd. | 3% | 35,588 | SCHEDULE 13G/A, 2025-11-14 | 2025-11-14 |
| L1 Capital Global Opportunities Master Fund, Ltd. | 3% | 35,589 | SCHEDULE 13G/A, 2025-11-14 | 2025-11-14 |
Holding shares or following this stake? See who's behind ENDRA Life Sciences Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on ENDRA Life Sciences Inc. and the records around it.
ENDRA Life Sciences Inc. elsewhere on the record
- Layoff notices Mar 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- ASP Isotopes Inc. also filed stake reports on 1 other company: Skyline Builders Group Holding Limited (Sep 2025)
- ATW Master Fund V LP also filed stake reports on 17 other companies: La Rosa Holdings Corp. (Oct 2026), Kandal M Venture Limited (Aug 2026), Fold Holdings, Inc. (May 2026)
- S.H.N. Financial Investments Ltd. also filed stake reports on 19 other companies: PRF Technologies Ltd. (Nov 2026), INLIF Ltd (Oct 2026), DarkIris Inc. (Oct 2026)
Watch ENDRA Life Sciences Inc.
Get an email when ENDRA Life Sciences Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ENDRA Life Sciences Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ENDRA Life Sciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ENDRA Life Sciences Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| ASP Isotopes Inc. | 0 | 254,015 | 0 | 254,015 | SCHEDULE 13D, 2026-10-08 |
| LHE LNG Holdings LLC | 0 | 254,015 | 0 | 254,015 | SCHEDULE 13D, 2026-10-08 |
| Anthony DiGiandomenico | 196,692 | 0 | 196,692 | 0 | SCHEDULE 13D/A, 2026-06-29 |
The latest filing identifies ENDRA Life Sciences Inc. by CUSIP 29273B500 and gives its principal executive office as 3600 GREEN COURT, SUITE 350, ANN ARBOR, MI 48105 (SCHEDULE 13D, 2026-10-08).
Source of funds (Item 3)
The Reporting Person purchased an aggregate of 70,824 shares of Common Stock from the market or in public or private offerings from 2020 to October 2025 using his personal funds. All other shares of Common Stock and derivative securities described in Item 5 below have been issued to the Reporting Person in connection with his services to the Issuer as a director.Anthony DiGiandomenico, SCHEDULE 13D/A, 2026-06-29
Purpose of Transaction (Item 4)
Anthony DiGiandomenico
On June 25, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among ASP Isotopes Inc., a Delaware corporation, Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ASP ("Noble"), Renergen Limited, a company incorporated under the laws of the Republic of South Africa and a direct, wholly-owned subsidiary of ASP , the Issuer, and Kruger Merger Sub LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of the Issuer ("Merger Sub"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Noble (the "Merger"), with Noble surviving the Merger as a direct wholly-owned subsidiary of the Issuer. Also on June 25, 2026, in connection with the Merger Agreement, the Issuer, Noble and the Reporting Person entered into a voting agreement (the "Voting Agreement"). Pursuant to the Voting Agreement, the Reporting Person has agreed, among other things, subject to the terms and conditions thereof, to: (i) vote their beneficially owned securities of the Issuer in favor of the approval of (A) the issuance of the shares of Class A Common Stock (as defined below) and Class B Common Stock (as defined below) of the Issuer as consideration in the Merger, (B) the implementation of a reverse stock split for the purpose of maintaining compliance with Nasdaq listing standards, if …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-29; the filing has the rest
ASP Isotopes Inc.
The information reported in Item 3 and Item 6 of this Schedule 13D is incorporated herein by reference. LHE LNG intends to exercise Pre-Funded Warrants to purchase 187,169 shares of Common Stock prior to the record date of the Special Meeting in order to vote such shares of Common Stock on any proposals on which it is entitled to vote at the Special Meeting. The Reporting Persons intend to review their investment in the Issuer on a continuing basis taking into consideration various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for shares of Common Stock of the Issuer, in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time, which may include further acquisitions of shares of Common Stock of the Issuer or disposal of some or all of the shares of Common Stock of the Issuer owned by the Reporting Persons or otherwise acquired by the Reporting Persons, either in the open market or in privately negotiated transactions. Any open market or privately negotiated purchases or sales, acquisition recommendations or proposals or other transactions concerning the Issuer may be made at any time without prior notice. Any alternative may …The first part of Item 4 of the SCHEDULE 13D filed 2026-10-08; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-28 | ATW Master Fund V LP | 9.9% | SCHEDULE 13G |
| 2025-10-30 | John Carter Lipman | 9.99% | SCHEDULE 13G |
| 2025-11-14 | S.H.N. Financial Investments Ltd. | 3% | SCHEDULE 13G/A |
| 2025-11-14 | L1 Capital Global Opportunities Master Fund, Ltd. | 3% | SCHEDULE 13G/A |
| 2025-11-26 | Anthony DiGiandomenico | 9.99% | SCHEDULE 13D |
| 2026-06-29 | Anthony DiGiandomenico | 9.9% | SCHEDULE 13D/A |
| 2026-10-08 | ASP Isotopes Inc. | 15.1% | SCHEDULE 13D |
Questions about who owns ENDRA Life Sciences Inc.
Who owns ENDRA Life Sciences Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of ENDRA Life Sciences Inc.: ASP Isotopes Inc. (15.1%, Schedule 13D, filed 2026-10-08), John Carter Lipman (9.99%, Schedule 13G, filed 2025-10-30), ATW Master Fund V LP (9.9%, Schedule 13G, filed 2025-10-28) and Anthony DiGiandomenico (9.9%, Schedule 13D/A, filed 2026-06-29).
Who are the largest shareholders of ENDRA Life Sciences Inc.?
By the share each holder's latest filing reports, the largest holders of ENDRA Life Sciences Inc. on this page are ASP Isotopes Inc. (15.1%), John Carter Lipman (9.99%) and ATW Master Fund V LP (9.9%).
When did ASP Isotopes Inc. buy into ENDRA Life Sciences Inc.?
The filings give report dates, not purchase dates. The earliest filing from ASP Isotopes Inc. on this page is the Schedule 13D, filed 2026-10-08, reporting 15.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for ENDRA Life Sciences Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 24, 2025 | Form D, private offering | $14.40M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for ENDRA Life Sciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.